🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  2. ZYTIGA 250 mg tablets, ZYTIGA 500 mg film-coated tablets, Apalutamide placebo, JNJ-56021927, PREDNISONE, -

    Pharma Mar S.A.

    Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. Zometa 4 mg/100 ml solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

  4. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  5. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    Novo Nordisk A/S

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume

    Novo Nordisk A/S

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  7. elafibranor, Elafibranor Placebo

    Ipsen Pharma

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  8. elafibranor, Placebo tablet

    Ipsen Pharma

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  9. lactose monohydrate - 100,00 mg/tablet cellulose microcrystalline - 95,60 mg/tablet Croscarmellose sodium - 2,00 mg/tablet Magnesium stearate - 2,40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON, Asmenol, 10 mg, tabletki powlekane

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  10. mannitol and microcrystalline cellulose, Tolebrutinib

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  11. nalbuphine HCl ER tablets 60 mg BID

    Trevi Therapeutics

    Uremic Pruritus

    phase 3 small molecule completed

    1 trial

  12. rilonacept 160 mg

    Regeneron UK Limited

    Familial Cold Autoinflammatory Syndrome (FCAS)

    phase 3 small molecule completed

    1 trial

  13. ziltivekimab, Placebo (ziltivekimab C)

    Novo Nordisk A/S

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  14. ziltivekimab, Ziltivekimab

    Novo Nordisk A/S

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  15. 60 mg PRAX-114 or 40 mg PRAX-114

    PRECISION BIOSCIENCES INC

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  16. 60 mg Prednisone

    United Therapeutics Europe Ltd

    Airway Inflammation

    phase 2 small molecule completed

    1 trial

  17. 601

    Sunshine Biopharma

    Pathological Myopic Choroidal Neovascularization

    phase 2 small molecule active

    1 trial

  18. 601 1.25mg

    Sunshine Biopharma

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  19. 608

    Sunshine Biopharma

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  20. 608 Dose A

    Sunshine Biopharma

    Ankylosing Spondylitis

    phase 2 small molecule active

    1 trial

  21. 609A

    Sunshine Biopharma

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  22. 89Zr-Bevacizumab

    Disc Medicine

    NF2-related schwannomatosis

    phase 2 small molecule active

    1 trial

  23. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

    Takeda Pharmaceuticals International AG

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

  24. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources